Sorafenib vs Nivolumab in Patients With Hepatocellular Carcinoma

Journal of Liver Research, Disorders & Therapy
doi 10.15406/jlrdt.2017.03.00081
Full Text
Abstract

Available in full text

Date
Authors
Publisher

MedCrave Group, LLC

Related search

Nivolumab in Advanced Hepatocellular Carcinoma: Sorafenib-Experienced Asian Cohort Analysis

Journal of Hepatology
Hepatology
2019English

Sorafenib in Hepatocellular Carcinoma

Clinical Medicine. Therapeutics
2009English

Attenuation of Liver Stiffness in Sorafenib-Treated Patients With Advanced Hepatocellular Carcinoma

Hepatoma Research
2017English

Sorafenib Combined With Hepatectomy in Patients With Intermediate-Stage and Advanced Hepatocellular Carcinoma

Archives of Medical Science
Medicine
2017English

Sorafenib With Transarterial Chemoembolization Achieves Improved Survival vs. Sorafenib Alone in Advanced Hepatocellular Carcinoma: A Nationwide Population-Based Cohort Study

Cancers
Cancer ResearchOncology
2019English

Early Α-Fetoprotein Response Predicts Survival in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib

Journal of Hepatocellular Carcinoma
2015English

Neutrophil-To-Lymphocyte Ratio Predicts Survival in European Patients With Hepatocellular Carcinoma Administered Sorafenib

Oncotarget
Oncology
2017English

Sorafenib Continuation or Discontinuation in Patients With Unresectable Hepatocellular Carcinoma After a Complete Response

Oncotarget
Oncology
2015English

Pcn17 - Indirect Treatment Comparisons of Nivolumab Versus Regorafenib, Cabozantinib and Best Supportive Care After Treatment With Sorafenib for Hepatocellular Carcinoma

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy